Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Global Cord Blood Corp. operates as a holding company, which engages in providing cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. It provides parents of newborn infants with umbilical cord blood storage services. The company was founded on January 17, 2008 and is headquartered in Hong Kong.

HONG KONG , Sept. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will hold its 2021 annual general meeting of shareholders at its Hong Kong office, located at 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, at 9:00 p.m.

Global Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 7, 2021

Global Cord Blood Corporation (CO) Q1 2022 Results - Earnings Call Transcript

1Q22 Added 19,673 New Subscribers Revenues Up 12.2% YoY to RMB315.2 Million ($48.8 Million) Gross Profit Up 12.6% YoY to RMB267.3 Million ($41.4 Million) Operating Income Up 17.3% YoY to RMB156.6 Million ($24.2 Million) Non-GAAP Operating Income Up 15.5% YoY to RMB168.5 Million ($26.1 Million) Conference Call to be Held on August 31, 2021, at 8:00 a.m. ET HONG KONG, Aug. 30, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the first quarter of fiscal 2022, ended June 30, 2021.

Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2022

HONG KONG, Aug. 25, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results for the first quarter fiscal 2022 on Monday, August 30, 2021, after the market close.  The Company will host a conference call at 8:00 a.m.

Global Cord Blood Corporation to Report First Quarter Fiscal 2022 Financial Results

Global Cord will benefit from China's tutoring regulatory changes due to higher disposable income for expecting parents and increased newborns.

Global Cord Blood Is An Undervalued Business With Accelerating Growth, Benefiting From China's Policy Changes

Global Cord Blood had a decent quarter, with subscriber growth improving both YoY and QoQ.

Global Cord Blood: New China Policy Catalyst, 146% Net Cash And 24% EPS CAGR

Global Cord Blood Corporation (CO) Management on Q4 2021 Results - Earnings Call Transcript

Added 19,367 New Subscribers in 4Q21 Revenues Up 0.8% YoY to RMB302.3 million ($46.1 million) Net Income Attributable Up 31.7% YoY to RMB127.7 million ($19.5 million) Operating Cash Flow Up 134.6% YoY to RMB211.1 million ($32.2 million) Conference Call to be Held on June 29, 2021 at 8:00 a.m. ET HONG KONG, June 28, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2021, ended March 31, 2021.

Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2021

HONG KONG, June 22, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release unaudited financial results for the fourth quarter and full year fiscal 2021 on Monday, June 28, 2021, after the U.S. market close.  The Company will host a conference call at 8:00 a.m.

Global Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results

HONG KONG, March 15, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that in response to the non-binding proposal letter dated March 2, 2021 received by the Company's Board of Directors (the "Board") from Alternate Ocean Investment Company Limited ("Alternate Ocean"), pursuant to which Alternate Ocean, acting on behalf of the fund (the "Acquirer") that it manages and/or advises, proposes to acquire all of the outstanding ordinary shares of the Company for US$5.00 per ordinary share in cash, subject to certain conditions. The Board has formed a special committee of independent directors who are not affiliated with Alternate Ocean (the "Special Committee") to evaluate such proposal.

Global Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal

The company received an acquisition offer.

Why Global Cord Blood Corporation Stock Is Jumping Today

Global Cord Blood Corporation (CO) CEO Albert Chen on Q3 2021 Results - Earnings Call Transcript

Global Cord Blood had a soft quarter, but subscriber growth continues unabated.

Global Cord Blood Corp.: Subscriber Growth Continues With 23% EPS CAGR And 25% FCF Yield

HONG KONG, Feb. 24, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial...

Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2021

HONG KONG, Feb. 19, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release unaudited...

Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2021 Financial Results

HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today reported that China's National Health...

Global Cord Blood Announces NHC Policy Update

CO is a market leader with more net cash than the market cap and our price target is $6.00 [45% upside]. 1HFY2021 results saw total subscriber numbers grow by 10%, despite tough operating conditions.

Global Cord Blood Corp.: Solid Subscriber Growth, Net Cash Greater Than Market Cap And High FCF Yield Of 25%

Global Cord Blood Corporation (CO) CEO Ting Zheng on Q2 2021 Results - Earnings Call Transcript

HONG KONG, Nov. 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial...

Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2021

Lam Research

Rattler Midstream Lp - Unit

Investors who are screening for value opportunities may want to consider the following stocks since their share prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-based discounted cash flow calculator.

3 Stocks That Could Be Deals

HONG KONG, Sept. 17, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will.

Global Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 7, 2020

Global Cord Blood Corporation: June Quarter YoY EPS Of 22%, Subscriber Growth, And Total 183% Net Cash

Global Cord Blood Corporation (CO) CEO Tina Zheng on Q1 2021 Results - Earnings Call Transcript

HONG KONG, Aug. 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial.

Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2021

Global Cord Blood: 20% EPS 5-Year CAGR, 17% FCF Yield - Investing In A Business For Free

News for Global Cord Blood Stock (CO)